Chronic Kidney Disease – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive agents and SGLT-2 inhibitors, which are intended to delay the disease’s progression. RAAS inhibitors are the standard of care for CKD, but newer agents from the SGLT-2 inhibitor and MRA classes could transform the treatment algorithm. In 2021, AstraZeneca’s Farxiga (dapagliflozin) became the first SGLT-2 inhibitor to demonstrate a renoprotective effect in a dedicated CKD outcomes trial and receive approval from the FDA for the treatment of CKD irrespective of the presence of diabetes. Also in 2021, Bayer’s MRA Kerendia (finerenone) received approval for CKD after it demonstrated renoprotective and cardioprotective benefits in type 2 diabetes patients with CKD in the FIDELIO-DKD and FIGARO-DKD trials. In 2022, Eli Lilly’s Jardiance (empagliflozin) demonstrated renoprotective benefits in the EMPA-KIDNEY trial.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CKD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CKD patients?
- How have Jardiance, Farxiga, and Kerendia been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of CKD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of CKD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key companies: AstraZeneca, Eli Lilly, Boehringer Ingelheim.
Key drugs: Jardiance, Farxiga, Invokana, Kerendia.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Chronic Kidney Disease - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Chronic Kidney Disease US March 2023
- Treatment Algorithms CDA Chronic Kidney Disease 2023 Dashboard
Dwaipayan Chatterjee, M.Pharm., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders analyst. Mr. Chatterjee authors reports on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.